Growth Metrics

Idexx Laboratories (IDXX) Cash from Financing Activities (2016 - 2026)

Idexx Laboratories has reported Cash from Financing Activities over the past 17 years, most recently at -$355.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 52.8% year-over-year to -$355.7 million; the TTM value through Dec 2025 reached -$1.2 billion, down 32.67%, while the annual FY2025 figure was -$1.2 billion, 32.67% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$355.7 million at Idexx Laboratories, down from -$313.3 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at -$13.5 million in Q1 2022 and troughed at -$355.7 million in Q4 2025.
  • A 5-year average of -$177.7 million and a median of -$158.3 million in 2023 define the central range for Cash from Financing Activities.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 41763.32% in 2021 and later soared 89.6% in 2022.
  • Year by year, Cash from Financing Activities stood at -$165.8 million in 2021, then grew by 29.61% to -$116.7 million in 2022, then increased by 12.75% to -$101.8 million in 2023, then crashed by 128.57% to -$232.8 million in 2024, then crashed by 52.8% to -$355.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for IDXX at -$355.7 million in Q4 2025, -$313.3 million in Q3 2025, and -$165.6 million in Q2 2025.